On October 7, 2024 Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, reported being selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2024, which is scheduled to be held November 6-10 at the George R. Brown Convention Center in Houston, Texas (Press release, Beyond Cancer, OCT 7, 2024, View Source [SID1234647068]). Abstracts are scheduled to be released to SITC (Free SITC Whitepaper) registrants on November 5, 2024, 9:00 AM U.S. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SITC Annual Meeting Presentations:
Title: Intratumoral Administration of Low Volume High-Concentration Nitric Oxide and Anti-rPD-L1 Treatment Leads to Prolonged Survival in MAT B III Tumor-Bearing Rats
Session Date and Time: Friday, November 8, 2024, 9:00 AM – 7:00 PM CDT
Session Type: Poster Presentation
Abstract Number: 723
Location: Exhibit Halls A B, George R. Brown Convention Center
Title: Intratumoral Administration of Low Volume Ultra-High Concentration Nitric Oxide and Immune Checkpoint Inhibitors in CT26 Tumor-Bearing Mice
Session Date and Time: Saturday, November 9, 2024, 9:00 AM – 8:30 PM CDT
Session Type: Poster Presentation
Abstract Number: 724
Location: Exhibit Halls A B, George R. Brown Convention Center
A copy of the ePublications can be accessed on the Science and Technology page of the Company’s website on November 7, 2024 at 9:00 am EDT.
About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.
About UNO Therapy for Solid Tumors
Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models. Beyond Cancer, Ltd. believes that UNO has the potential to prevent relapse or metastatic disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects.